BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9827982)

  • 1. Rhinocerebral mucormycosis following donor leukocyte infusion: successful treatment with liposomal amphotericin B and surgical debridement.
    Peñalver FJ; Romero R; Forés R; Cabrera R; Díez-Martin JL; Regidor C; Fernández MN
    Bone Marrow Transplant; 1998 Oct; 22(8):817-8. PubMed ID: 9827982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia.
    Salonen JH
    Acta Biomed; 2006; 77 Suppl 2():28-31. PubMed ID: 16918065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful donor leukocyte infusion for chronic myeloid leukemia relapsing in accelerated phase after T cell-replete unrelated marrow transplantation.
    Grigg A; Szer J
    Bone Marrow Transplant; 1996 Sep; 18(3):647-8. PubMed ID: 8879633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML.
    Rahman SL; Mahendra P; Nacheva E; Sinclair P; Arno J; Marcus RE
    Bone Marrow Transplant; 1998 May; 21(9):955-6. PubMed ID: 9613792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation.
    Leleu X; Sendid B; Fruit J; Sarre H; Wattel E; Rose C; Bauters F; Facon T; Jouet J
    Bone Marrow Transplant; 1999 Aug; 24(4):417-20. PubMed ID: 10467332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
    Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
    J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment with donor leukocyte transfusion followed by interferon-alpha in a patient with relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation].
    Maeda A; Yamamoto K; Kotone Y; Yamashita K; Yoshinaga N; Hirata H; Asagoe K; Nohgawa M; Takahashi A; Ohno H; Tashima M; Sasada M
    Rinsho Ketsueki; 1998 Jun; 39(6):442-6. PubMed ID: 9695673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
    Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Donor leukocyte transfusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation].
    Itoh T; Hatta Y; Miyajima T; Simojima H; Sawada U; Horie T
    Rinsho Ketsueki; 1998 Jun; 39(6):409-15. PubMed ID: 9695667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of rhinocerebral mucormycosis by combination of endoscopic sinus debridement and amphotericin B.
    Alobid I; Bernal M; Calvo C; Vilaseca I; Berenguer J; Alós L
    Am J Rhinol; 2001; 15(5):327-31. PubMed ID: 11732820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
    Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B treatment for rhinocerebral mucormycosis: how much is enough?
    Handzel O; Landau Z; Halperin D
    Rhinology; 2003 Sep; 41(3):184-6. PubMed ID: 14579660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rhinocerebral mucormycosis. Apropos of a case].
    Escalante Avila A; Medina Gómez J; de Juan Ivars C; Portell Soriano M; Fernández Vega M
    Acta Otorrinolaringol Esp; 1989; 40(1):51-2. PubMed ID: 2629928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
    Inai K; Wano Y; Yamamoto S; Ikebata Y; Iwasaki H; Tsutani H; Naiki H; Ueda T
    Anticancer Res; 1999; 19(6C):5631-4. PubMed ID: 10697631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhinocerebral mucormycosis with orbital and intracranial extension: a case report and review of optimum management.
    Munir N; Jones NS
    J Laryngol Otol; 2007 Feb; 121(2):192-5. PubMed ID: 17134533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhinocerebral Mucormycosis: consideration of prognostic factors and treatment modality.
    Jung SH; Kim SW; Park CS; Song CE; Cho JH; Lee JH; Kim NS; Kang JM
    Auris Nasus Larynx; 2009 Jun; 36(3):274-9. PubMed ID: 18786790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.